

Biotage appoints Andrew Kellett as Interim CFO

Biotage appoints Andrew Kellett as its Interim CFO. Andrew is currently CFO of Astrea Bioseparations, which was acquired by Biotage earlier this year. He will take the Biotage CFO role as of 25 September 2023. As previously announced, Maja Nilsson has decided to leave the position as CFO at Biotage for new challenges. Recruitment of a permanent successor as CFO continues.

Contacts

Tomas Blomquist, President and CEO
Tel: 0705 23 01 63, tomas.blomquist@biotage.com

About Biotage

Biotage is a Global Impact Tech Company committed to solving society's problems. We offer workflow solutions and products to customers in drug discovery and development and diagnostics, analytical testing and water and environmental testing.

Biotage is contributing to sustainable science with the goal to make the world a healthier, greener and cleaner place – Humankind Unlimited.

Our customers span a broad range of market segments including pharmaceutical, biotech, diagnostic, contract research and contract manufacturers as well as clinical, forensic and academic laboratories in addition to organizations focused on food safety, clean water and environmental sustainability.

Biotage is headquartered in Uppsala in Sweden and employs appr. 700 people worldwide. The Group had sales of 1,566 MSEK in 2022 and our products are sold in more than 80 countries. Biotage's share (BIOT) is listed in the Large Cap segment on the NASDAQ Stockholm. Website: www.biotage.com

Attachments

[Biotage appoints Andrew Kellett as Interim CFO](#)